Positron emission tomography fluorodeoxyglucose

ATawakol, R.Q. Migrino, U. Hoffmann, S Abbara, S Houser, H Gewirtz, J.E. Muller, T.J Brady, A.J Fischman, Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography, J. Nucl. Cardiol. 12 (2005) 294-301. [Pg.138]

J.H.F. Rudd, K.S. Myers, S. Bansilal, J. Machac, A. Rafique, M. Farkouh, V. Fuster, Z.A. Fayad, Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible Implications for atherosclerosis therapy trials, J. Am. Coll. Cardiol. 50 (2007) 892-896. [Pg.138]

N. Tahara, H. Kai, M. Ishibashi, H. Nakaura, H. Kaida, K. Baba, N. Hayabuchi, T. Imaizumi, Simvastatin attenuates plaque inflammation Evaluation by fluorodeoxyglucose positron emission tomography, J. Am. Coll. Cardiol 48 (2006) 1825-1831. [Pg.138]

M. Dietlein, W. Weber, M. Schwaiger, H. Schicha, F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer, Nuklearmedizin 42(4) (2003) 145-156. [Pg.182]

M. Mukai, S. Sadahiro, S. Yasuda, H. Ishida, N. Tokunaga, T. Tajima, H. Makuuchi, Preoperative evaluation by whole-body F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer, Oncol. Rep. 7(1) (2000) 85-87. [Pg.183]

L. Staib, H. Schirrmeister, S.N. Reske, H.G. Beger, Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making. Am. J. Surg. 180(1) (2000) 1-5. [Pg.183]

H.L. van Westreenen, M. Westerterp, P.M. Bossuyt, J. Pruim, G.W. Sloof, J.J. van Lanschot, H. Groen, J.T. Plukker, Systematic review of the staging performance of F-fluorodeoxyglucose positron emission tomography in esophageal cancer, J. Clin. Oncol. 22(18) (2004) 3805-3812. [Pg.186]

R.J. Downey, T. Akhurst, M. Gonen, A. Vincent, M.S. Bains, S. Larson, V. Rusch, Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection, J. Clin. Oncol. 22(16) (2004) 3255-3260. [Pg.187]

S.G. Stroobants, I. D Hoore, C. Dooms, P.R. De Leyn, P.J. Dupont, W.W. De, G. T. De, J.A. Verschakelen, L.A. Mortelmans, J.F. Vansteenkiste, Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer, Clin. Lung Cancer 4(4) (2003) 242-247. [Pg.188]

N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W.A. Weber, M. Werner, H. Graeff, M. Schwaiger, W. Kuhn, Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer, J. Clin. Oncol. 23(30) (2005) 7445-7453. [Pg.188]

S. Stanzei, B. Asadpour, K. Hamacher, H.H. Coenen, U. Buell, M.J. Eble, [ F] fluoromisonidazole and [ F] fluorodeoxyglucose positron emission tomography in response evaiuation after chemo-/radiotherapy of non-small-cell lung cancer A feasibility study, BMC Cancer 6 (2006) 51. [Pg.192]

Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000 48(1) 105-108. [Pg.180]

Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G (1989) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging 25,79-83. [Pg.197]

Rahn AN, Baum RP, Adamietz lA, Adams S, Sengupta S, Mose S, Bormeth SB, Hor G, Bottcher HD (1998) Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors. Strahlenther Onkol 174 358-364... [Pg.166]

Sura S, Greco C, Gelblum D, Yorke ED, Jackson A, Rosenzweig KE (2008) (18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 70 1397-1402... [Pg.166]

Diehl M, Risse JH, Brandt-Mainz K etal. (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer results of a multicentre study. Eur J Nucl Med 28 1671-1676... [Pg.479]

Pasquali C, Rubello D, Sperti C etal. (1998) Neuroendocrine tumor imaging can F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior World J Surg 22 588-592... [Pg.480]

Lewandowski RJ, Thurston KG, Goin JE et al (2005) °Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vase Interv Radiol 16 1641-1651... [Pg.88]

Donckier V, Van Laethem JL, Goldman S et al (2003) [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 84 215-223... [Pg.150]

Dubey N, Miletich RS, Wasay M, et al. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 2002 205(1) 77-81. [Pg.216]

Bandoh S, Fujita J, Yamamoto Y, Nishiyama Y, Ueda Y, Tojo Y, Ishii T, Kubo A, Ishida T (2003) A case of lung cancer associated with pneumoconiosis diagnosed by fluorine-18 fluorodeoxyglucose positron emission tomography. Ann Nucl Med 17 597-600... [Pg.89]

Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) is being used with increased frequency to aid diagnosis and staging of malignancy. Pleural metastases cause increased FDG activity. A case is reported in which increased FDG activity, presumed to be due to pleural inflamma-... [Pg.272]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...